Speciality Medicines Ltd (544738)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Speciality Medicines' revenue was ₹45.0 Cr (+45.2% year on year), and net profit ₹8.0 Cr (+166.7% year on year); the operating margin was 17.8%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹45.0 | +45.2% | — |
| Operating profit | ₹8.0 | +100.0% | — |
| Net profit | ₹8.0 | +166.7% | — |
| EPS (₹) | 9.31 | +123.8% | — |
| Operating margin | 17.8% | — | — |
📢 Recent Corporate Announcements
Speciality Medicines Ltd has received regulatory approval for two new speciality pharmaceutical formulations in Ethiopia: Olanzapine 5mg (Olazyn 5) and Diazepam 5mg (Diazem 5). This increases the company's total registered product portfolio in the Ethiopian market to 12 formulations. The company also maintains a presence in Peru with 2 registered formulations. Given the company's FY26 revenue of ₹75.0 Cr and a high ROCE of 25.0%, these incremental approvals support its export-led growth strategy in semi-regulated markets.
- Received regulatory approval for 2 new speciality formulations: Olanzapine 5mg and Diazepam 5mg
- Total registered product portfolio in Ethiopia increased to 12 formulations
- Maintains a presence in Peru with 2 registered formulations
- FY26 revenue grew to ₹75.0 Cr from ₹58.0 Cr in FY25, a 29.3% increase
- Company maintains a healthy ROCE of 25.0% and low Debt/Equity of 0.10
Speciality Medicines Ltd has secured regulatory approvals for two Central Nervous System (CNS) products, Olanzapine and Diazepam, in Ethiopia. This expansion brings the company's total registered products in Ethiopia to 12 and its global total to 14 (including Peru). With FY26 revenue at ₹75 Cr, these approvals are part of a strategic push to scale international exports, which currently support a high ROCE of 25%.
- 2 new product registrations received for Olanzapine (Antipsychotic) and Diazepam (Anxiolytic) in Ethiopia
- Total registered product portfolio increased to 14 formulations across Ethiopia and Peru
- Registration validity for the new products is fixed at 5 years
- Company maintains a group portfolio of 900+ speciality formulations for potential future filings
- FY26 revenue grew to ₹75 Cr from ₹58 Cr in FY25, representing a 29% year-on-year increase
Speciality Medicines Ltd has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency as of August 04, 2026. The move is intended to enhance engagement with institutional and retail investors and improve corporate transparency. This follows a strong FY26 performance where the company reported a revenue of ₹75.0 Cr and a net profit of ₹13.0 Cr, up from ₹58.0 Cr and ₹9.0 Cr respectively in FY25. The company maintains a healthy balance sheet with a low Debt-to-Equity ratio of 0.10.
- Appointment of Capital Bridge Advisory Service Private Limited as IR/PR agency on August 04, 2026
- Company reported FY26 revenue of ₹75.0 Cr, representing 29.3% growth over FY25
- Net profit increased to ₹13.0 Cr in FY26 from ₹9.0 Cr in the previous fiscal year
- Maintains a low debt profile of ₹7 Cr against a net worth of ₹71 Cr as of latest filings
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
